PMID- 23595117
OWN - NLM
STAT- MEDLINE
DCOM- 20131204
LR  - 20220316
IS  - 1423-0216 (Electronic)
IS  - 1021-7401 (Linking)
VI  - 20
IP  - 3
DP  - 2013
TI  - TRAF2 is upregulated in relapsing-remitting multiple sclerosis.
PG  - 177-83
LID - 10.1159/000346794 [doi]
AB  - OBJECTIVE: To elucidate the role of tumor necrosis factor (TNF) receptor signal 
      transduction in multiple sclerosis (MS). METHODS: We performed a cross-sectional 
      analysis of the gene expression of TRAF2 (TNF receptor-associated factor 2) and 
      RIP (receptor-interacting protein) in peripheral blood leukocytes of 23 
      relapsing-remitting (RR), 19 secondary progressive (SP) and 12 primary 
      progressive (PP) MS patients as well as of 29 healthy controls by quantitative 
      RT-PCR. Additionally, we monitored a subgroup of 15 RRMS patients longitudinally 
      every 3 months over a 9-month time period. RESULTS: TRAF2 expression was 
      significantly elevated in RRMS patients compared to the other disease courses 
      (p<0.005, respectively) and the control group (p<0.009). RIP expression was 
      significantly elevated in the patient groups compared to the healthy group 
      (phealthy-RR<0.002; phealthy-PP<0.003; phealthy-SP<0.06). Neither variable 
      changed over the 9-month time course. CONCLUSION: TRAF2 and RIP1 elevation in 
      leukocytes might be interpreted as the molecular equivalent of an elevated 
      general inflammatory activity in MS patients compared to healthy control persons. 
      TRAF2 elevation in RRMS reinforces the concept that different pathophysiological 
      and immunological processes sustain RRMS and SPMS or PPMS.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
FAU - Reuss, Reinhard
AU  - Reuss R
AD  - Department of Neurology, Bezirkskrankenhaus Bayreuth, Bayreuth, Germany. 
      reinhard.reuss.email1@gmx.de
FAU - Mirau, Andreas
AU  - Mirau A
FAU - Mistarz, Marta
AU  - Mistarz M
FAU - Kraus, Jorg
AU  - Kraus J
FAU - Bodeker, Rolf-Hasso
AU  - Bodeker RH
FAU - Oschmann, Patrick
AU  - Oschmann P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130405
PL  - Switzerland
TA  - Neuroimmunomodulation
JT  - Neuroimmunomodulation
JID - 9422763
RN  - 0 (AGFG1 protein, human)
RN  - 0 (Nuclear Pore Complex Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (TNF Receptor-Associated Factor 2)
SB  - IM
MH  - Cross-Sectional Studies
MH  - Disease Progression
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Leukocytes/metabolism
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/*genetics/physiopathology
MH  - Nuclear Pore Complex Proteins/genetics/metabolism
MH  - RNA, Messenger/metabolism
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Severity of Illness Index
MH  - TNF Receptor-Associated Factor 2/genetics/*metabolism
MH  - Up-Regulation/*physiology
EDAT- 2013/04/19 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/06/18 00:00 [received]
PHST- 2012/12/14 00:00 [accepted]
PHST- 2013/04/19 06:00 [entrez]
PHST- 2013/04/19 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 000346794 [pii]
AID - 10.1159/000346794 [doi]
PST - ppublish
SO  - Neuroimmunomodulation. 2013;20(3):177-83. doi: 10.1159/000346794. Epub 2013 Apr 
      5.